173089-24-2

Basic information

• Product Name: 2-bromomethyl-5-thiazolecarboxylic acid ethyl ester
• Synonyms: 2-bromomethyl-5-thiazolecarboxylic acid ethyl ester;Ethyl 2-(bromomethyl)thiazole-5-carboxylate;Ethyl 2-(Bromomethyl)Thiazole-5-Carboxylate(WX618437)
• CAS NO: 173089-24-2
• Molecular Formula: C7H8BrNO2S
• Molecular Weight: 250.11292
• Mol File: 173089-24-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-bromomethyl-5-thiazolecarboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromomethyl-5-thiazolecarboxylic acid ethyl ester(173089-24-2)
• EPA Substance Registry System: 2-bromomethyl-5-thiazolecarboxylic acid ethyl ester(173089-24-2)

Safety Data

• Hazardous Substances Data: 173089-24-2(Hazardous Substances Data)

Upstream product

• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 
• 79836-78-5 ethyl 2-methylthiazole-5-carboxylate 

Relevant articles and documents

Novel 4-trifluoromethylthiazole-5-carboxylic acid as acceptor in photosensitized dyes

Novel photosensitized dyes containing 4-trifluoromethyl-thiazole-5- carboxylic acid as an acceptor are synthesized. Stilbene-type dyes with this acceptor show high performance as dye-sensitized solar cells. The trifluoromethyl group is assumed to act as a suppressor of electron back-donation from the TiO2 conduction band to the electrolyte and as an accelerator of charge separation in the photoexcited state.

SULFONAMIDE COMPOUND OR SALT THEREOF

[Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP 1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.

Compounds

PCT No. PCT/SE98/00940 Sec. 371 Date Jun. 10, 1998 Sec. 102(e) Date Jun. 10, 1998 PCT Filed May 18, 1998 PCT Pub. No. WO98/54180 PCT Pub. Date Dec. 3, 1998The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.